FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 447 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations MOST POPULAR Hormone Replacement Therapy Not Linked with Increased Dementia Risk, Study Finds October 2, 2021 Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with... July 25, 2024 EMA Recommends Extension of Therapeutic Indications for Tisagenlecleucel May 4, 2022 Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly... August 31, 2020 Load more HOT NEWS How NatWest Group are making a difference this Giving Tuesday Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint... First immunotherapy approved for cervical cancer in England and Scotland CancerLand Bookshelf : Loosen
